Piper Sandler raised its AbbVie price target to $349 from $303, citing strong Skyrizi growth and early promise from combination-drug trials. Its target implies 23% upside from the Nov. 19 close and values AbbVie at about 19 times estimated 2028 earnings. The article says the target depends on earnings growth and 2027 guidance, with Apogee costs and Medicare pricing for Vraylar among the risks.
AbbVie agrees to pay DISCO up to $2.5 billion for cancer collaboration
AbbVie and DISCO Pharmaceuticals will collaborate to discover and develop AND-gated bispecific therapeutics for solid tumors, combining DISCO’s surfaceome-mapping platform with AbbVie’s oncology expertise. DISCO will receive $40 million upfront and could earn up to $2.5 billion in option, development and other milestone payments, plus tiered royalties. AbbVie may exclusively license selected programs after research activities.
AbbVie raises 2026 outlook after third-quarter growth
AbbVie reported third-quarter sales of $17.4 billion and adjusted EPS of $3.82, with growth from Skyrizi, Rinvoq and neuroscience products offsetting Humira’s decline. It raised its 2026 revenue guidance, including higher outlooks for its immunology and neuroscience franchises. The articles also cite risks including product concentration, competition, pricing pressure and weakness in aesthetics and oncology.
Barclays raised its AbbVie price target to $335 from $325 and maintained an Overweight rating, citing strong third-quarter revenue growth and robust Skyrizi and Rinvoq sales. The target implies a 21x forward earnings multiple. The article notes potential 2027 headwinds from Apogee-related costs and Medicare pricing for Vraylar, and says fourth-quarter results and initial 2027 guidance will be a test.
AbbVie expands migraine collaboration and enters AI drug discovery partnership
AbbVie expanded its Brise Pharmaceuticals collaboration, gaining global development and commercialization rights for preclinical migraine programs, and entered an AI-driven drug discovery partnership with Iambic. The deals support pipeline development in neuroscience as AbbVie seeks to offset revenue declines from older drugs, but their impact depends on future clinical progress and milestones.
AbbVie reported positive Phase 3 TEMPLE results showing QULIPTA was better tolerated and more effective than topiramate for migraine prevention. Side-effect-related discontinuation was 12% with QULIPTA versus 30% with topiramate over 24 weeks. The findings support QULIPTA’s competitive position and AbbVie’s neuroscience strategy, though commercial impact will depend on sales traction.
Allergan Aesthetics reports results from two GLP-1 patient studies
In HARMONY IN DIVERSITY’s 30-person medical weight loss cohort, combined hyaluronic acid fillers, onabotulinumtoxinA and skincare produced a statistically significant 42.4-point improvement in satisfaction with facial appearance. Interim HALO results from 25 participants showed a 39.6-point improvement; 95.7% were satisfied or very satisfied that they still looked like themselves. Most treatment-related adverse events were mild and nonserious.
AbbVie ranks among healthcare stocks highlighted after midterm elections
AbbVie ranked 10th on a list of healthcare stocks favored after the 2026 Democratic midterm sweep, with support from 88 hedge funds. Third-quarter revenue rose 10.3% year over year as Skyrizi and Rinvoq helped offset a decline in Humira. The article notes that election-related expectations around Medicaid and ACA policy affect insurers and hospitals more directly than pharmaceutical companies.
AbbVie licenses Nxera inflammatory bowel disease drug for up to $1.37 billion
AbbVie agreed to license Nxera Pharma’s oral EP4 agonist for inflammatory bowel disease in a deal worth up to $1.37 billion, while Nxera retains certain co-funding and royalty interests. AbbVie is also expanding UK research with a new Oxford facility focused on immunology, neuroscience and oncology. The article describes the initiatives as part of AbbVie’s effort to replenish its pipeline.
Analysts weigh AbbVie growth against Vraylar pricing pressure
The articles discuss AbbVie’s valuation and the outlook for growth from Skyrizi and Rinvoq, alongside Vraylar’s expected IRA-mandated price beginning in 2027. Vraylar is expected to generate $4.2 billion in 2026 sales, while Imbruvica has faced IRA and competitive pressure. The articles also cite uncertainty around AbbVie’s 2027 outlook and possible pressure on Vraylar sales.
AbbVie shares have gained 36.6% over the past year and 29% year to date, outperforming the S&P 500 and pharmaceutical ETF PJP. Growth in key products, including Skyrizi, Rinvoq, and Vraylar, helped drive double-digit revenue growth across nine products. AbbVie beat Q3 earnings and revenue estimates, and forecasts full-year adjusted EPS of $13.95–$13.99. Analysts expect 39.9% EPS growth this year; all four recent quarterly earnings reports exceeded consensus. Of 31 analysts, 22 rate the stock a Strong Buy, two a Moderate Buy, and seven a Hold. The average target of $302.37 implies 2.6% upside, while the highest target of $350 implies 18.7%.
24/7 Wall St. rates AbbVie shares Hold after earnings-driven rise
AbbVie rose after third-quarter adjusted EPS beat expectations, revenue grew 10.3%, and the company raised its full-year EPS guidance and quarterly dividend. Skyrizi and Rinvoq sales grew strongly, while Humira, Imbruvica and Juvederm declined. The article cited valuation and drug-pricing risks, alongside pipeline developments and Skyrizi’s Crohn’s launch.
AbbVie reports Phase 2 remission results for Crohn’s drug combination
AbbVie’s Phase 2 ABBV-466 combination of Skyrizi and trosunilimab achieved higher Crohn’s endoscopic remission rates than either drug alone: 40.5% at week 24 versus 22.4% and 20%, respectively. Serious adverse events were slightly more frequent with the combination. The results are promising for Skyrizi lifecycle management, but the treatment remains years from potential approval and requires Phase 3 confirmation.
RBC raises AbbVie price target to $330 and maintains Outperform rating
AbbVie shares fell 2.32% to $288.06 despite RBC raising its price target to $330 and maintaining an Outperform rating. In the third quarter, Skyrizi and Rinvoq generated a combined $8.482 billion, about 12.4 times Humira’s $683 million and 48.7% of total revenue. RBC sees potential for continued immunology growth and improved margins, while the article also notes valuation and product-concentration risks.